The government finally fast-tracked LSD as an anxiety treatment.
MindMed, the first publicly traded pharmaceutical company focused on psychedelics, said its drug has received a breakthrough designation from the FDA.
Read moreComparing MDMA and LSD
Different psychedelics show unique promise for treating mental illness, from PTSD to depression and anxiety. This article compares MDMA and LSD.
Read moreLSD and Brain Connections
This study, published in the Journal of Psychopharmacology, found that LSD “not only increases the strength of certain brain connections but weakens other connections at the same time,” according to a digest of the study in Psychedelic Spotlight.
Read moreLSD, Psychosis and Healing
The link between psychosis model and therapeutic model seems to lie in mystical experiences.
The results point to the importance of meaning attribution for the LSD psychosis model and indicate that psychedelic-assisted therapy might benefit from therapeutic suggestions fostering mystical experiences.
Read moreAn LSD Analogue and Therapeutic Potential
Microdosing LSD - No Long-term Changes Found
A new study on microdosing LSD did not find any beneficial long-term changes in mood or cognition.
Read moreYour Brain on LSD
In a newly published study, researchers look at what happens to your brain on LSD.
Read moreLSD History
She was a personal acquaintance of Albert Hofmann, the scientist who first synthesised LSD and noted its psychedelic effects 80 years ago, in April 1943.
Read moreGlobal Survey 2020 Results: Self-Treatment of LSD and Psilocybin
Positive changes were observed across all 17 outcome items, with the strongest benefits on items related to insight and mood. Negative effects were reported by 22.5% of respondents.
High intensity of psychedelic experience, seeking advice before treatment, treating with psilocybin mushrooms and treating post-traumatic stress disorder were associated with higher scores on the self-treatment outcome scale after averaging values across all 17 items.
Younger age, high intensity of experience and treating with LSD were associated with increased number of negative outcomes.
Read moreA Non-Hallucinogenic LSD Analog?
BetterLife Pharma Inc., an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that findings from a study on its lead candidate BETR-001 (2-bromo-LSD) titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders” has been published in the peer-reviewed journal of Cell Report.
What do you think?
Read more